New drug combo challenges chemo for Intermediate-Risk CLL
NCT ID NCT04010968
First seen Jan 07, 2026 · Last updated May 14, 2026 · Updated 22 times
Summary
This study tested whether a combination of two targeted drugs (venetoclax and ibrutinib) works better than standard chemotherapy (FCR) for people with intermediate-risk chronic lymphocytic leukemia (CLL) who have not been treated before. About 120 fit adults took part. The treatment was tailored based on how well the cancer responded, with the goal of stopping the drugs once the cancer was deeply suppressed. The study aimed to see if this approach could improve outcomes and reduce the need for long-term medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERMEDIATE RISK CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bordeaux Pessac
Pessac, 33604, France
-
CH Annecy Genevois - Hématologie A3
Annecy, 74374, France
-
CH BLOIS
Blois, 41000, France
-
CHD Vendée
La Roche-sur-Yon, 85925, France
-
CHR ORLEANS - Hématologie
Orléans, 44100, France
-
CHU Caen - IHBN - Hématologie Clinique
Caen, 14033, France
-
CHU Estaing - Hématologie Clinique Adulte
Clermont-Ferrand, 63000, France
-
CHU Grenoble - Hématologie
Grenoble, 388043, France
-
CHU Hôtel Dieu - Hématologie Clinique
Nantes, 44093, France
-
CHU Nancy Brabois
Vandœuvre-lès-Nancy, 54500, France
-
CHU Pontchaillou - Hématologie Clinique BMT-HC
Rennes, 35033, France
-
Centre Henri Becquerel - Service Hématologie Clinique
Rouen, 76038, France
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495, France
-
Centre Hospitalier Regional Metz Thionville
Metz, 57085, France
-
Centre Hospitalier Sud Francilien
Corbeil-Essonnes, 91100, France
-
Centre Hospitalier du Mans
Le Mans, 72000, France
-
Centre Léon Bérard - Hématologie
Lyon, 69373, France
-
Ch Cote Basque
Bayonne, 64109, France
-
Chu Creteil
Créteil, 94000, France
-
Chu Reims
Reims, 51092, France
-
GRENOBLE GHM - Institut Daniel Hollard
Grenoble, 38028, France
-
Hôpital André Mignot
Versailles, 78157, France
-
Hôpital Avicenne - Centre de Recherche Clinique
Bobigny, 93009, France
-
Hôpital Bretonneau - Hématologie et Thérapie Cellulaire
Tours, 37044, France
-
Hôpital Hautepierre - Hématologie
Strasbourg, 67098, France
-
Hôpital Pitié Salpétrière - Hématologie
Paris, 75651, France
-
Hôpital Privé Sévigné
Cesson-Sévigné, 35510, France
-
Hôpital Saint Eloi
Montpellier, 34295, France
-
Hôpital Saint Vincent de Paul
Lille, 59000, France
-
Hôpital de la Milétrie - Hématologie et Thérapie Cellulaire
Poitiers, 86021, France
-
IUCT ONCOPOLE - Hématologie
Toulouse, 31059, France
-
Institut Bergonie
Bordeaux, 33076, France
-
Institut Paoli Calmette
Marseille, 130009, France
-
Institut de Cancérologie Lucien Neuwirth
Saint-Priest-en-Jarez, 42271, France
Conditions
Explore the condition pages connected to this study.